SCHEMBL3016080

SCHEMBL3016080

COc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3cccc(Br)c3)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
USP2 O75604 2/20 0.46
HSD17B10 Q99714 2/20 0.46
RECQL P46063 1/20 0.46
KMT2A Q03164 4/20 0.45
GFER P55789 2/20 0.45
MEN1 O00255 2/20 0.45
GBA1 P04062 1/20 0.43
RAB9A P51151 1/20 0.43
GAA P10253 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 2/20 0.42
LMNA P02545 1/20 0.42
GLA P06280 1/20 0.42
MAPK1 P28482 1/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.42
PKM P14618 1/20 0.41
HDAC3 O15379 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013480 0.91 MAPT (0.48) MAPTUSP2HSD17B10RECQLKMT2A
SCHEMBL3005437 0.91 TP53 (0.48) MAPTUSP2HSD17B10RECQLKMT2A
SCHEMBL3022582 0.90 ALDH1A1 (0.48) MAPTUSP2HSD17B10RECQLKMT2A
SCHEMBL3017596 0.89 GFER (0.59) MAPTUSP2HSD17B10RECQLKMT2A
SCHEMBL3015005 0.89 MAPT (0.46) MAPTUSP2HSD17B10RECQLKMT2A
SCHEMBL3012549 0.88 GBA1 (0.45) MAPTUSP2HSD17B10RECQLKMT2A
SCHEMBL3015038 0.88 HSD17B10 (0.57) MAPTUSP2HSD17B10RECQLGBA1
SCHEMBL3015128 0.88 GAA (0.51) MAPTUSP2RECQLKMT2AMEN1
SCHEMBL3014141 0.87 GAA (0.51) MAPTUSP2HSD17B10RECQLKMT2A
SCHEMBL3016767 0.87 USP2 (0.43) MAPTUSP2HSD17B10RECQLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.